Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kalaris Therapeutics (KLRS) Free Cash Flow (2019 - 2020)

Kalaris Therapeutics (KLRS) has 2 years of Free Cash Flow data on record, last reported at -$21.1 million in Q4 2020.

  • For Q4 2020, Free Cash Flow fell 134.65% year-over-year to -$21.1 million; the TTM value through Dec 2020 reached -$60.8 million, changed N/A, while the annual FY2024 figure was -$67.7 million, 45.6% up from the prior year.
  • Free Cash Flow reached -$21.1 million in Q4 2020 per KLRS's latest filing, down from -$18.1 million in the prior quarter.
  • Across five years, Free Cash Flow topped out at -$6.4 million in Q3 2019 and bottomed at -$21.1 million in Q4 2020.